Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

A Divalent Immunotoxin Formed by the Disulfide Bond between Hinge Regions of Fab Domain

  • Published : 20011200
Download PDF
⟨ Previous Next ⟩

Abstract

Recombinant immunotoxins are hybrid cytotoxic proteins designed to selectively kill cancer cells. A divalent immunotoxins, [B3(FabH1)-PE38]2, was constructed by recombining Fab domain of B3 antibody as a cell-targeting domain and Pseudo monas exotoxin A (PE) as a cytotoxic domain. Monoclonal antibody, B3, is the murine antibody (IgG1k) directed against Lewis Y-related carbohydrate antigens, which are abundant on the surface of many carcinomas. Fab fragment of this antibody was used in this study with the modified hinge sequence where last two cysteines out of three were mutated to serine. PE is a 66 kDa bacterial toxin that kills eukaryotic cells by inhibiting protein synthesis with ADP ribosylation of ribosomal elongation factor 2 (EF2). Fc region of B3 antibody was substituted with the truncated form of PE (38 kDa, PE38) on DNA level. [B3(FabH1)-PE38]2 was formed by disulfide bond between cysteines in the modified hinge region of B3(FabH1)-PE38. Each polypeptide for recombinant immunotoxins was overexpressed in Escherichia coli and collected as inclusion bodies. Each inclusion body was solubilized and refolded, and cytotoxic effects were measured. Divalent immunotoxins, [B3(FabH1)-PE38]2, had ID50 values of about 10 ng/mL on A431 cell lines and about 4 ng/mL on CRL1739 cell lines. Control immunotoxins, B3(scFv)-PE40, had ID50 values of about 28 ng/mL on A431 cell lines and about 41 ng/mL on CRL1739 cell lines. Divalent immunotoxins, [B3(FabH1)-PE38]2, had higher cytotoxic effects than B3(scFv)-PE40 control immunotoxins.

Keywords

References

  1. J. Clin. Oncol. v.9 Pai, L. H.;Bookman, M. A.;Ozols, R. F.;Young, R. C.;Smith, J. W. II.;Longo, D. L.;Gould, B.;Frankel, A.;McClay, E. F.;Howell, S.;Reed, E.;Willingham, M. C.;FitzGerald, D. J.;Pastan, I.
  2. Protein Engineering v.13 Schmiedl, A.;Breitling, F.;Dubel, S.
  3. J. Immunol. Methods v.231 Hudson, P. J.;Kortt, A. A.
  4. Int. J. Cancer v.81 Kreitman, R. J.;Wang, Q. C.;FitzGerald, D. J.;Pastan, I.
  5. Br. J. Cancer v.77 Deonarain, M. P.;Epenetos, A. A.
  6. Exp. Cell. Res. v.258 Baluna, R.;Coleman, E.;Jones, C.;Ghetie, V.;Vitetta, E. S.
  7. Bio/Technology v.10 Buchner, J.;Brinkmann, U.;Pastan, I.
  8. Proc. Natl. Acad. Sci. U S A v.95 Chowdhury, P. S.;Viner, J. L.;Beers, R.;Pastan, I.
  9. J. Clin. Invest. v.74 FitzGerald, D. J.;Waldmann, T. A.;Willingham, M. C.;Pastan, I.
  10. Int. J. Cancer v.58 Reiter, Y.;Kreitman, R. J.;Brinkmann, U.;Pastan, I.
  11. Am. J. Surg. v.166 Theuer, C. P.;Pastan, I.
  12. Proc. Natl. Acad. Sci. USA v.88 Brinkmann, U.;Pai, L. H.;FitzGerald, D. J.;Willingham, M.;Pastan, I.
  13. Cancer Res. v.52 Pai, L. H.;Batra, J. K.;FitzGerald, D. J.;Willingham, M. C.;Pastan, I.
  14. Biotechnology (NY) v.10 Buchner, J.;Brinkmann, U.;Pastan, I.
  15. J. Mol. Biol. v.268 Brinkmann, U.;Di Carlo, A.;Vasmatzis, G.;Kurochkina, N.;Beers, R.;Lee, B.;Pastan, I.
  16. Int. J. Cancer v.67 Reiter, Y.;Wright, A. F.;Tonge, D. W.;Pastan, I.
  17. Cancer Res. v.59 Bera, T. K.;Viner, J.;Brinkmann, E.;Pastan, I.
  18. Bioconjug. Chem. v.9 Bera, T. K.;Pastan, I.
  19. Cancer Res. v.54 Choe, M.;Webber, K. O.;Pastan, I.
  20. Cancer Res. v.53 Kreitman, R. J.;Hansen, H. J.;Jones, A. L.;FitzGerald, D. J.;Goldenberg, D. M.;Pastan, I.
  21. Cancer Res. v.52 Debinski, W.;Pastan, I.
  22. Mol. Immunol. v.32 Kurucz, I.;Titus, J. A.;Jost, C. R.;Segal, D. M.
  23. Curr. Opin. Biotechnol. v.9 Lilie, H.;Schwarz, E.;Rudolph, R.
  24. Protein Eng. v.10 Rajagopal, V.;Pastan, I.;Kreitman, R. J.
  25. Biotechnol. Prog. v.11 Burks, E. A.;Iverson, B. L.
  26. Biotechnol. Appl. Biochem. v.28 Suenaga, M.;Ohmae, H.;Tsuji, S.;Itoh, T.;Nishimura, O.
  27. Protein Expr. Purif. v.7 Johnson, D. L.;Middleton, S. A.;McMahon, F.;Barbone, F. P.;Kroon, D.;Tsao, E.;Lee, W. H.;Mulcahy, L. S.;Jolliffe, L. K.
  28. Anal. Biochem. v.205 Buchner, J.;Pastan, I.;Brinkmann, U.
  29. Shih Yen Sheng Wu Hsueh Pao v.26 Xu, Y. H.;Peng, S. F.;Jiang, W. L.;Zhu, Y.;Chandhary, V.;FitzGerald, D.;Pastan, I.
  30. J. Biol. Chem. v.265 Batra, J. K.;FitzGerald, D.;Gately, M.;Chaudhary, V. K.;Pastan, I.
  31. FEBS Lett. v.441 Martsev, S. P.;Kravchuk, Z. I.;Chumanevich, A. A.;Vlasov, A. P.;Dubnovitsky, A. P.;Bespalov, I. A.;Arosio, P.;Deyev, S. M.
  32. Proc. Natl. Acad. Sci. USA v.89 Brinkmann, U.;Buchner, J.;Pastan, I.
  33. Proc. Natl. Acad. Sci. USA v.88 Pai, L. H.;Batra, J. K.;FitzGerald, D. J.;Willingham, M. C.;Pastan, I.
  34. Cancer Res. v.54 Reiter, Y.;Pai, L. H.;Brinkmann, U.;Wang, Q. C.;Pastan, I
  35. Cancer Res. v.53 Camera, L.;Kinuya, S.;Pai, L. H.;Garmestani, K.;Brechbiel, M. W.;Gansow, O. A.;Paik, C. H.;Pastan, I.;Carrasquillo, J. A.
  36. Clin. Cancer Res. v.2 Scherf, U.;Benhar, I.;Webber, K. O.;Pastan, I.;Brinkmann, U.